PART-A: Threat-Analysis as a Strategy to Manage Uncertainty
Using an INOVIS proprietary strategy-gaming exercise, participants will be provided with a business case study and suggested frameworks to perform threat analysis, in order to:
• Apply new analytical frameworks to a pharma-like business case study in a learning environment
• Evaluate the importance of comprehensive & robust threat assessments and the impact these can have on strategic decision making (commercial readiness, development programs, BD opportunities, forecasting, scenario planning, mitigation plans, etc.)
• Acquire ideas and initiatives that can be rapidly integrated into ongoing CI Practice
PART-B: Gx/Biosimilar CI Assessments and Strategic Framework
Leveraging a specific Gx / biosimilar example, the second part of this workshop will address and highlight best practices when implementing follow-up activities related to identified actions during a strategic gaming exercise, this interactive workshop session will specifically enable you to:
• Get to the core issues at hand and the appropriate CI solution
• Identify appropriate analytical activities
• Set up a best-in-industry Gx/biosimilar RI and CI tracking program
• Understand Gx / Biosimilar product development and entry strategies
• Identify potential actions to optimize launches
Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.
Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.
In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.
This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.
But there is little agreement on a definition for digital solutions and rarely a focused strategy to make them profitable. This session will present a framework for conceptualizing digital solutions and thinking through the market opportunity and competitive landscape for a range of digital solutions.
Presented by Bayer and Merck & Co.
Presented by Google
Topics we will cover:
• Scoping a project and preparing the brief
• Choosing an agency
• Interacting with the agency during the project
• Delivery of the project results
The audience can expect to be able to participate actively in the “conversation” and contribute to the program
Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis
Presented by Abbvie
Presented by Novartis
CI professionals play a key role in preparing for successful deals. This discussion will focus on how CI can support a large array of DD activities beyond the preparation of a competitive landscape. DD projects provide extraordinary opportunity for CI professionals to deliver outstanding value to the business by supporting and leading hosts of activities within the DD process. This discussion is intended to help raise awareness of the many ways CI can deliver value for DD projects.
Presented by Eagle Pharmaceuticals
In some Monet paintings, there are lots of dots of color, but only until you back-up that you see the whole picture. The question we’ll dig into is, who is putting the painting in a frame to create a cohesive picture or do we just have multiple painters with information, but no cohesiveness to it all.
Presented by Merck
Presented by BioMarin
During the early stages of product development, CI tends to be undervalued due to the high risk of failure which means low or zero budget. However, including CI in the early stages of development can help optimise clinical programs to be more competitive on the market. For example, learning from the failures of your competitors.
This talk will address the following questions and provide some ideas on how to plan and execute successful CI projects during the early stages of drug development.
• Why is it important to understand the market and its competitors prior to launch?
• When to begin planning pre‐launch CI projects?
• What types of information can be gathered?
Presented by Lifescience Dynamics
Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders’ perception.
One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:
1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion
In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.
Presented by Atacana Group
• What are the opportunities for the CI function in such a dynamic market? How can these opportunities be realized?
• What can CI functions and managers do to ensure their intelligence continues to drive value, growth, and strategy?
Presented by Deallus
Old-school and business-as-usual methodologies and deliverables will not cut it in an ever-changing business and technological environment that demands greater efficiencies in collection and analysis, and greater demands on ROI effectiveness of CI deliverables. As the American-Canadian writer William Gibson once said, “The future is already here – it’s just not very evenly distributed.” Prescient has surveyed CI stakeholders and has captured a list of the top challenges faced by CI teams. We will discuss the industry “norms” and the advent of budding new and futuristic solutions that will shake up the way we think of CI.
Presented by Prescient Healthcare Group
How the new tools can be used to facilitate our roles within Strategic Intelligence?
How can we integrate secondary, primary and artificial intelligence for the benefit of our internal stakeholders?
Presented by GlobalReach BI
Acquisitions such as the CVS/Aetna merger and the Walgreens/Express Scripts group purchasing alliance are indications of new trends in the market. These trends have the potential to significantly change how decisions are made in the market. This session will present a set of future scenarios that depict the market based on extension of the trends. Using interactive tools, participants will model out strategies that pharmaceutical companies will need to implement to thrive in the environment.
Key Take-aways:
1. New thinking about how the traditional pharmaceutical market will change by 2030
2. Expanded awareness of potential impacts from alliances between health insurance carriers, pharmacies, and pharmacy benefits managers
3. Exploration into ways the government can intervene in the market based on different scenarios
4. Broad strategic options for pharmaceutical companies
Presented by Fletcher/CSI
However, some basic truths still hold strong. This session will address Marjorie’s experience – the good, the bad and the ugly – in developing and maintaining a best-in-class CI program.
Presented by Cambridge Healthcare Research
In this session, we’ll go beyond the hype and show the real value that AI and NLP can add to your competitive intelligence processes. Answering questions, such as how are competitors talking about you, your products, and your market? Or, how does your peer’s business guidance compare to yours?
You’ll learn:
• How these technologies can directly answer the most critical questions posed by Competitive Intelligence analysts
• How applied AI can save Competitive Intelligence teams hundreds of hours of work each month
• Where these technologies can provide competitive insights unreachable with the legacy approach to research
Presented by Sentieo
Some are opportunistic, namely conferences, arranged meetings, and internal strategic focus areas. Other methods deploy bottom-up approaches looking at company performance measures, such as clinical success and financial info. Lastly, some strategists prefer the top-down approach, namely analyzing trends across a wide variety of medical conditions to look for an emerging molecular target, modality or new treatments. This allows for a better understanding of the formation and dynamics of the trend, and how much potential it holds (if any) to become effective, and ubiquitous, and expandable. In this presentation, Dr. Madar will focus on recent technology trends, emphasize and characterize one of them, and provide examples for leading entities in this field.
Presented by Signals Analytics
Combined with rising public scrutiny on drug prices, this trend will increasingly drive pharma suppliers toward value-based contracting. This session will define ‘value-based contracting,’ provide examples of different types of arrangements, present obstacles to adoption, and explain how pharma companies can play a more proactive role in the evolution toward ‘value-based care.’
Presented by DuckerFrontier
Challenges include: defining your role, understanding the expertise you bring to the table, amplifying your voice, winning buy-in, measuring your success, knowing when and how to expand.
Presented by Pfizer
In the case we will look at a product launch and how initial targeting used best available data and intelligence. We will explore what happened post launch and discuss how soon should you change your strategy if the results are not what was expected. Do you need to have a wealth of data to make a change?
Presented by Amneal Pharmaceuticals
Presented by Promius Pharma
Presented by Eli Lilly and Company
Presented by Amicus Therapeutics, GlaxoSmithKline, Ionis Pharmaceuticals, Sanofi Pasteur, and Sobi
Presented by Alnylam Pharmaceuticals, Daiichi Sankyo, Ipsen Biopharmaceuticals, and Taiho Oncology
Presented by Align Strategy, The Dunn Group, and Roche Diagnostics
Presented by Abbott Laboratories
Presented by Summit Therapeutics
This understanding helps target the right product in order gain market share and the right customer (HCP) in order to increase promotional impact. The combination of these and other steps together helps define a winning launch strategy.
Presented by Lupin Pharmaceuticals
Artificial intelligence, while just a piece of this technological equation, has the power to accelerate strategic partnerships and growth by providing visibility into the market for competitive intelligence professionals.
For those in the industry, knowledge of regulatory activities, FDA drug approvals, and the shifting M&A landscape is critical to competitive intelligence. Join AlphaSense for an informative session about AI’s future impact on pharma and how it is currently transforming the role of the competitive intelligence analyst.
Learn how AI can…
– Quickly access and monitor important competitive information to enable focused research and deliver meaningful insights
– Fuel analysis and build confidence in seeing the bigger picture
– Empower teams to make smarter decisions by leveraging the latest data and news
Presented by AlphaSense
The increased use of social media to share opinions regarding emerging data from conferences and tradeshows by patients, researchers, health care providers, and key thought leaders provides a new opportunity for pharmaceutical companies to improve understanding of perception related to developing and existing therapeutic approaches. While social media platforms provide basic search capabilities, subscription-based services provide the ability to analyze all social media activity from an event while offering powerful insights into user communities, influence of specific individuals, and the most widely discussed presentations and events from an event. During this presentation, we’ll share outputs from this type of analysis and share thoughts about how these activities fit into a comprehensive conference monitoring approach.
Presented by Proactive Worldwide
Presented by Osprey Health Consulting
Presented by Healthcare Intelligence and Analytics
“Design Thinking” and its application across the whole organisation
Digital transformation and the rise of the Chief Digital Officer
Presented by Dig Worldwide
In this presentation we discuss how to view CI through a statistical/probabilistic lens. The discussion is motivated through the Let’s Make a Deal game show to understand how to leverage prior knowledge about an event and factor in new information through CI. The discussion will demystify Markov Chain Monte Carlo simulation methods and show how these methods can be used to help generate insights into a probability model of product launch timings. Combining launch timings with drug feature sets ( safety, efficacy and dosing ) we will show how to gain qualitative insight into NBRx. This discussion will not be a forecasting seminar and no advanced degrees are required. The objective of the talk is to provide talking points so that you can discuss with your Advanced Analytics team on how to model product launches based on competitive intelligence information and understand potential uptake of products.
Presented by Roche
Oftentimes, our department goals and objectives are difficult to achieve without budget to support external, specialized agency support. Attend this session to understand key strategies to develop and achieve wins with your functional and brand team in advance of budget time. Key short-term wins will enable you to capture stakeholder buy-in and budget for future projects.
Presented by Ionis Pharmaceuticals
What does big pharma need to know and what is being missed? How will prescription digital therapeutics (PDTs) be reimbursed? How will medical policies and drug formularies change as PDTs enter the market? As physicians, patients, and payers embrace technology to drive better treatment outcomes at lower costs, pharma companies are getting aligned to optimize their competitive positions. This session will provide the needed insight.
Presented by Click Therapeutics
They’ll share their thoughts on:
• How vendors view clients and how they define a successful relationship
• How clients view vendors and why they decide to work with one over another
• How to measure success.
• Do’s and don’ts from both sides of the table
• Better ways to partner
Presented by Merck
Presented by Abbvie
Presented by Novartis
CI professionals play a key role in preparing for successful deals. This discussion will focus on how CI can support a large array of DD activities beyond the preparation of a competitive landscape. DD projects provide extraordinary opportunity for CI professionals to deliver outstanding value to the business by supporting and leading hosts of activities within the DD process. This discussion is intended to help raise awareness of the many ways CI can deliver value for DD projects.
Presented by Eagle Pharmaceuticals
In some Monet paintings, there are lots of dots of color, but only until you back-up that you see the whole picture. The question we’ll dig into is, who is putting the painting in a frame to create a cohesive picture or do we just have multiple painters with information, but no cohesiveness to it all.
Presented by Merck
Presented by BioMarin
A handful of corporate behemoths, most created very recently, control huge portions, sometimes majority shares, of the insurance, distribution, and retail and pharmacy businesses. These vertically aligned giants will influence – often control — 80% of prescriptions. Their pricing power is increasing almost exponentially.
Meanwhile, in the still relatively free-market world of the US, governments are becoming increasingly agitated – with the Federal government threatening, among other things, European-style price indexing while the States are introducing a raft of initiatives, including laws, like California’s, requiring drug firms to justify price increases.
The biopharma industry’s response has largely been to back as rapidly as it can into what it perceives is the pricing immunity of rare diseases: new approvals in these categories constitute more than half of the industry’s output. Companies are thus drastically improving the lives of a very small number of people and paying for the pricing flexibility with often substantially increased patient costs and, as an industry, a shrinking medical importance to society as a whole.
This talk will discuss these issues and their business implications, as well as possible ways forward for the industry and in particular, the new capabilities successful companies will require.
Presented by Real Endpoints
With seemingly endless “on-demand”, “tailored”, “agile” and “VUCA-driven” solutions touching our professional and personal lives every day, this session seeks to address what best practices, ideas and solutions can be leveraged into our working practices to generate further impact to our teams, stakeholders and wider organizations. Delivered by two leading CI industry experts, the INOVIS team looks forward to an engaging, dynamic and hopefully provocative audience participation-driven approach, which will leave you with a fresh outlook on the future of CI in the Pharmaceutical industry and how to optimize your personal impact on decision making!
Presented by INOVIS
Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis